Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Canagliflozin after metabolic surgery may aid weight loss, reduce glucose levels

Publish date:: May 13, 2019

Key clinical point: Canagliflozin after metabolic surgery improved weigh loss outcomes and blood glucose levels.

Major finding: At 6 months, fasting glucose was significantly reduced in patients who took canagliflozin group (from 163 mg/dL to 122 mg/dL; P = .007).

Study details: A prospective, randomized, controlled trial of 16 patients with type 2 diabetes who underwent metabolic surgery.

Disclosures: Janssen provided funding for the trial.

Citation:

REPORTING FROM AACE 2019

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Gender surgical outcomes differ following puberty suppression,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Diabetes

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

Semaglutide shows promise in NASH phase 2 study,

‘Modest’ benefit for post-MI T2D glucose monitoring,

Diabetic neuropathic pain linked to brain bioenergic anomalies,